Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background and objectives

High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131 lipiodol on survival and recurrence.

Methods

Between 2004 and 2010, 38 patients were treated with adjuvant I-131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I-131 lipiodol treatment became available.

Results

Recurrence-free survival in the control and in the I-131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014).

Conclusions

Adjuvant I-131 lipiodol improves disease-free survival in patients with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bruix J, Sherman M (2005) Practice guidelines committee AAftSoLD management of hepatocellular carcinoma. Hepatology 42(1208–123):6

    Google Scholar 

  2. Jelic S (2010) Sotiropoulos GC. Group EGW Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up annals of oncology : official journal of the European Society for Medical Oncology/ESMO 21(Suppl 5):v59–v64

    Article  Google Scholar 

  3. Huang J, Yan L, Cheng Z et al (2010) A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Annals of surgery 252(903–91):2

    Google Scholar 

  4. Liu JG, Wang YJ, Du Z (2010) Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis. World J Gastroenterol 16(3450–345):6

    Google Scholar 

  5. Lai EC, Lau WY (2005) The continuing challenge of hepatic cancer in Asia Surgeon. The Surgeon 3(210–21):5

    Google Scholar 

  6. Llovet JM, Burroughs A (2003) Hepatocellular carcinoma. Lancet 362(1907–191):7

    Google Scholar 

  7. Belghiti J, Panis Y, Farges O et al (1991) Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214(114–11):7

    Google Scholar 

  8. Ercolani G, Grazi GL, Ravaioli M et al (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237(536–54):3

    Google Scholar 

  9. Tanaka H, Kubo S, Tsukamoto T et al (2005) Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transpl Proc 37(1254–125):6

    Google Scholar 

  10. Poon RT, Fan ST, Ng IO et al (2000) Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 231(544–55):1

    Google Scholar 

  11. Zhong JH, Li H, Li LQ et al (2012) Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 38(286–29):5

    Google Scholar 

  12. Li JQ, Zhang YQ, Zhang WZ et al (1995) Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 121(364–36):6

    Google Scholar 

  13. Peng BG, He Q, Li JP et al (2009) Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198(313–31):8

    Google Scholar 

  14. Yoo HS, Park CH, Lee JT et al (1994) Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 33(Suppl):S128–S133

    Article  PubMed  Google Scholar 

  15. Lau WY, Leung TW, Ho SK et al (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797–801

    Article  CAS  PubMed  Google Scholar 

  16. Lau WY, Lai EC, Leung TW et al (2008) Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5 year and 10 year survival. Ann Surg 247:43–48

    Article  PubMed  Google Scholar 

  17. Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data New York. Wiley, New York

    Google Scholar 

  18. Lau WY (2002) Management of hepatocellular carcinoma. J R Coll Surg Edinb 47:389–399

    CAS  PubMed  Google Scholar 

  19. Shimada M, Takenaka K, Gion T et al (1996) Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 111:720–726

    Article  CAS  PubMed  Google Scholar 

  20. Shi M, Zhang CQ, Zhang YQ et al (2004) Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 28(376–38):1

    Google Scholar 

  21. Wong IH, Yeo W, Leung T et al (2001) Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett 167:183–191

    Article  CAS  PubMed  Google Scholar 

  22. Fan ST, Yang ZF, Ho DW et al (2011) Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg 254(569–57):6

    Google Scholar 

  23. Poon RT, Fan ST, Ng IO et al (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89(500–50):7

    Google Scholar 

  24. Lau WY, Lai EC, Lau SH (2009) The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepat Pancreat Dis Int 8:124–133

    CAS  Google Scholar 

  25. Madsen MT, Park CH, Thakur ML (1988) Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 29:1038–1044

    CAS  PubMed  Google Scholar 

  26. Lui WY, Liu RS, Chiang JH et al (1990) Report of a pilot study of intra-arterial injection of I-131 lipiodol for the treatment of hepatoma. Zhonghua Yi Xue Za Zhi (Taipei) 46:125–133

    CAS  Google Scholar 

  27. Chung AY, Ooi LL, Machin D et al (2013) Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg 37:1356–1361

    Article  CAS  PubMed  Google Scholar 

  28. Dumortier J, Decullier E, Hilleret MN et al (2014) Adjuvant intraarterial lipiodol or 131I-lipiodol after curative treatment of hepatocellular carcinoma: a prospective randomized trial. J Nucl Med 55:877–883

    Article  CAS  PubMed  Google Scholar 

  29. Boucher E, Bouguen G, Garin E et al (2008) Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med 49:362–366

    Article  PubMed  Google Scholar 

  30. Chua TC, Chu F, Butler SP et al (2010) Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer 116:4069–4077

    Article  PubMed  Google Scholar 

  31. Tabone M, Vigano L, Ferrero A et al (2007) Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 33:61–66

    Article  CAS  PubMed  Google Scholar 

  32. Ng KM, Niu R, Yan TD et al (2008) Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB 10:388–395

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Partensky C, Sassolas G, Henry L et al (2000) Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 135:1298–1300

    Article  CAS  PubMed  Google Scholar 

  34. Furtado R, Crawford M, Sandroussi C (2014) Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma. Ann Surg Oncol 21:2700–2707

    Article  PubMed  Google Scholar 

  35. Gong L, Shi L, Sun J et al (2014) Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis. Nucl Med Commun 35:484–492

    Article  CAS  PubMed  Google Scholar 

  36. Tabone M, Vigano L, Laudi et al.(2005) Adjuvant iodine-131-labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: which is the best treatment schedule? Hepatology: 41, 1433; author reply 1433–1434

  37. Raoul JL, Boucher E, Roland V et al (2009) 131-iodine Lipiodol therapy in hepatocellular carcinoma. Q J Nucl Med Mol Imaging 53:348–355

    PubMed  Google Scholar 

  38. Oger E, Lavenu A, Bellissant E et al (2011) Meta-analysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approach. Pharmacoepidemiol Drug Saf 20:956–963

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Nikki Sabourin-Gibbs, Rouen University, Hospital Medical Editor, for editing the manuscript.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Rouen University Hospital-Charles Nicolle, Rouen, France

    Lilian Schwarz, Emmanuel Huet & Michel Scotté

  2. Department of Nuclear Medicine, Henri Becquerel Center and Rouen University Hospital, Rouen, France

    Isabelle Gardin & Pierre Vera

  3. Department of Biostatistics, Rouen University Hospital, Rouen, France

    Michael Bubenheim

  4. Department of Hepatogastroenterology, Rouen University Hospital, Rouen, France

    Ghassan Riachi & Odile Goria

  5. Department of Radiology, Rouen University Hospital, Rouen, France

    Erick Clavier

Authors
  1. Lilian Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Bubenheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabelle Gardin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuel Huet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ghassan Riachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erick Clavier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Odile Goria
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pierre Vera
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michel Scotté
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lilian Schwarz.

Ethics declarations

Confict of interest

LS, MB, IG, EH, GR, EC, OG, PV and MS have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schwarz, L., Bubenheim, M., Gardin, I. et al. Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma. World J Surg 40, 1941–1950 (2016). https://doi.org/10.1007/s00268-016-3502-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-016-3502-5

Keywords

Search

Navigation